{"id":25895,"date":"2024-08-06T11:57:48","date_gmt":"2024-08-06T09:57:48","guid":{"rendered":"https:\/\/ggba.swiss\/?p=25895"},"modified":"2024-08-06T11:57:53","modified_gmt":"2024-08-06T09:57:53","slug":"ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy","status":"publish","type":"post","link":"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/","title":{"rendered":"AC Immune receives FDA Fast Track designation for Alzheimer\u2019s disease therapy"},"content":{"rendered":"\n<p>Based in Lausanne, <a href=\"https:\/\/www.acimmune.com\/\">AC Immune<\/a> is a clinical-stage biopharmaceutical company specializing in precision medicine for neurodegenerative diseases. The company\u2019s technologies, SupraAntigen\u00ae and Morphomer\u00ae, support a diverse pipeline of first- and best-in-class therapeutic candidates.<\/p>\n\n\n\n<p>The investigational drug JNJ-2056, derived from AC Immune\u2019s SupraAntigen\u00ae platform, aims to generate broad-spectrum protective antibodies against pathological Tau. This approach may reduce Tau aggregation and slow disease progression in Alzheimer\u2019s patients. In clinical studies, JNJ-2056 has shown promise by inducing a strong antibody response against pathological Tau forms.<\/p>\n\n\n\n<p>The FDA&#8217;s Fast Track designation acknowledges the potential of AC Immune\u2019s therapy to provide significant benefits to patients. Andrea Pfeifer, CEO of AC Immune SA, stated, \u201cFast Track designation is an important recognition of the differentiation and potential value for patients of our anti-pTau active immunotherapy, ACI-35.030. The Phase 2b ReTain study is the first time any active immunotherapy is being tested in a preclinical AD population. We believe this modality has the potential to offer therapeutic advantages, as well as benefits in terms of convenience and access.\u201d<\/p>\n\n\n\n<h4 class=\"wp-block-heading\">Innovative solutions for Alzheimer\u2019s disease and neurodegenerative disorders<\/h4>\n\n\n\n<p>The development of JNJ-2056 is being conducted under a global license agreement with Janssen Pharmaceuticals, Inc. Janssen is fully funding and conducting the Phase 2b ReTain trial, which is currently recruiting participants with preclinical Alzheimer\u2019s disease who have not yet shown clinical symptoms.<\/p>\n\n\n\n<p>This new milestone builds on AC Immune\u2019s previous achievements, including <a href=\"https:\/\/ggba.swiss\/en\/ac-immune-and-takeda-sign-usd-100-million-deal-to-treat-alzheimers-disease\/\">a significant partnership with Takeda for the ACI-24.060 immunotherapy<\/a>. With the continued advancement of its therapeutic pipeline, AC Immune remains at the forefront of innovative solutions for Alzheimer\u2019s disease and other neurodegenerative disorders. The company&#8217;s efforts aim to provide new hope for millions of patients and their families worldwide.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>AC Immune\u2019s ACI-35.030 (now called JNJ-2056), an active-immunotherapy candidate targeting the pathologic form of the Tau protein, has received Fast Track designation from the U.S. Food and Drug Administration (FDA).<\/p>\n","protected":false},"author":6,"featured_media":25896,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"mc4wp_mailchimp_campaign":[],"footnotes":""},"categories":[833],"tags":[890,902,911,886],"class_list":["post-25895","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-life-science","tag-healthcare","tag-personalized-medicine","tag-pharma","tag-rd"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>AC Immune receives FDA Fast Track for Alzheimer\u2019s therapy<\/title>\n<meta name=\"description\" content=\"AC Immune\u2019s active-immunotherapy candidate targeting the pathologic form of the Tau protein, has received Fast Track designation from the FDA.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"AC Immune receives FDA Fast Track for Alzheimer\u2019s therapy\" \/>\n<meta property=\"og:description\" content=\"AC Immune\u2019s active-immunotherapy candidate targeting the pathologic form of the Tau protein, has received Fast Track designation from the FDA.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/\" \/>\n<meta property=\"og:site_name\" content=\"Greater Geneva Bern area\" \/>\n<meta property=\"article:published_time\" content=\"2024-08-06T09:57:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-08-06T09:57:53+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1180\" \/>\n\t<meta property=\"og:image:height\" content=\"811\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Pierre-Yves Oehrli\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Pierre-Yves Oehrli\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/\"},\"author\":{\"name\":\"Pierre-Yves Oehrli\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"headline\":\"AC Immune receives FDA Fast Track designation for Alzheimer\u2019s disease therapy\",\"datePublished\":\"2024-08-06T09:57:48+00:00\",\"dateModified\":\"2024-08-06T09:57:53+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/\"},\"wordCount\":302,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg\",\"keywords\":[\"Healthcare\",\"Personalized Medicine\",\"Pharma\",\"R&amp;D\"],\"articleSection\":[\"Life sciences\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/\",\"url\":\"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/\",\"name\":\"AC Immune receives FDA Fast Track for Alzheimer\u2019s therapy\",\"isPartOf\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg\",\"datePublished\":\"2024-08-06T09:57:48+00:00\",\"dateModified\":\"2024-08-06T09:57:53+00:00\",\"author\":{\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\"},\"description\":\"AC Immune\u2019s active-immunotherapy candidate targeting the pathologic form of the Tau protein, has received Fast Track designation from the FDA.\",\"breadcrumb\":{\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/#primaryimage\",\"url\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg\",\"contentUrl\":\"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg\",\"width\":1180,\"height\":811,\"caption\":\"AC Immune is a clinical-stage biopharmaceutical company dedicated to becoming a global leader in precision medicine for neurodegenerative diseases. | \u00a9 AC Immune\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/ggba.swiss\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"AC Immune receives FDA Fast Track designation for Alzheimer\u2019s disease therapy\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#website\",\"url\":\"https:\/\/staging.ggba.swiss\/en\/\",\"name\":\"Greater Geneva Bern area\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41\",\"name\":\"Pierre-Yves Oehrli\",\"url\":\"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"AC Immune receives FDA Fast Track for Alzheimer\u2019s therapy","description":"AC Immune\u2019s active-immunotherapy candidate targeting the pathologic form of the Tau protein, has received Fast Track designation from the FDA.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/","og_locale":"en_US","og_type":"article","og_title":"AC Immune receives FDA Fast Track for Alzheimer\u2019s therapy","og_description":"AC Immune\u2019s active-immunotherapy candidate targeting the pathologic form of the Tau protein, has received Fast Track designation from the FDA.","og_url":"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/","og_site_name":"Greater Geneva Bern area","article_published_time":"2024-08-06T09:57:48+00:00","article_modified_time":"2024-08-06T09:57:53+00:00","og_image":[{"width":1180,"height":811,"url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg","type":"image\/jpeg"}],"author":"Pierre-Yves Oehrli","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Pierre-Yves Oehrli","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/#article","isPartOf":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/"},"author":{"name":"Pierre-Yves Oehrli","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"headline":"AC Immune receives FDA Fast Track designation for Alzheimer\u2019s disease therapy","datePublished":"2024-08-06T09:57:48+00:00","dateModified":"2024-08-06T09:57:53+00:00","mainEntityOfPage":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/"},"wordCount":302,"commentCount":0,"image":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg","keywords":["Healthcare","Personalized Medicine","Pharma","R&amp;D"],"articleSection":["Life sciences"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/","url":"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/","name":"AC Immune receives FDA Fast Track for Alzheimer\u2019s therapy","isPartOf":{"@id":"https:\/\/staging.ggba.swiss\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/#primaryimage"},"image":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/#primaryimage"},"thumbnailUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg","datePublished":"2024-08-06T09:57:48+00:00","dateModified":"2024-08-06T09:57:53+00:00","author":{"@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41"},"description":"AC Immune\u2019s active-immunotherapy candidate targeting the pathologic form of the Tau protein, has received Fast Track designation from the FDA.","breadcrumb":{"@id":"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/#primaryimage","url":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg","contentUrl":"https:\/\/ggba.swiss\/app\/uploads\/2024\/08\/AC-Immune-Lausanne-EPFL-1180x811-1.jpg","width":1180,"height":811,"caption":"AC Immune is a clinical-stage biopharmaceutical company dedicated to becoming a global leader in precision medicine for neurodegenerative diseases. | \u00a9 AC Immune"},{"@type":"BreadcrumbList","@id":"https:\/\/ggba.swiss\/en\/ac-immune-receives-fda-fast-track-designation-for-alzheimers-disease-therapy\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/ggba.swiss\/en\/"},{"@type":"ListItem","position":2,"name":"AC Immune receives FDA Fast Track designation for Alzheimer\u2019s disease therapy"}]},{"@type":"WebSite","@id":"https:\/\/staging.ggba.swiss\/en\/#website","url":"https:\/\/staging.ggba.swiss\/en\/","name":"Greater Geneva Bern area","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/staging.ggba.swiss\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/staging.ggba.swiss\/en\/#\/schema\/person\/0b2e6d04131e3d01237dcb741fa33d41","name":"Pierre-Yves Oehrli","url":"https:\/\/ggba.swiss\/en\/author\/pierre-yves-oehrli\/"}]}},"_links":{"self":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/25895","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/comments?post=25895"}],"version-history":[{"count":1,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/25895\/revisions"}],"predecessor-version":[{"id":25899,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/posts\/25895\/revisions\/25899"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media\/25896"}],"wp:attachment":[{"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/media?parent=25895"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/categories?post=25895"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ggba.swiss\/en\/wp-json\/wp\/v2\/tags?post=25895"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}